Meeting
2015 ASCO Annual Meeting
Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial.
Authors
Oleg Gluz
West German Study Group, Moenchengladbach, Germany
Oleg Gluz , Ulrike Nitz , Matthias Christgen , Eva-Maria Grischke , Helmut Forstbauer , Michael Wilhelm Braun , Mathias Warm , Christoph Uleer , Bahriye Aktas , Claudia Schumacher , John Hackmann , Nikola Bangemann , Peter Staib , Christoph Lindner , Sherko Kummel , Cornelia Liedtke , Ronald E. Kates , Rachel Wuerstlein , Hans Heinrich Kreipe , Nadia Harbeck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Clinical Trial Registration Number
NCT01815242
Citation
J Clin Oncol 33, 2015 (suppl; abstr 1032)
DOI
10.1200/jco.2015.33.15_suppl.1032
Abstract #
1032
Poster Bd #
146
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Pathological complete response rate and survival in patients with BRCA-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).
First Author: Lisa Katharina Katharina Richters
Poster
2017 ASCO Annual Meeting
Association of molecular subtype, proliferation, and immune genes with efficacy of carboplatin versus gemcitabine addition to taxane-based, anthracycline-free neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Results of the randomized WSG ADAPT-TN trial.
First Author: Oleg Gluz
Poster
2018 ASCO Annual Meeting
Impact of 12 weeks nab-paclitaxel + carboplatin or gemcitabine followed by anthracycline administration according to pCR in triple-negative early breast cancer: Survival results of WSG-ADAPT-TN phase II trial.
First Author: Oleg Gluz
Poster
2018 ASCO Annual Meeting
Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).
First Author: Lajos Pusztai